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Hopkins R3,Tarride JE3
1Innsbruck Medical University, Innsbruck, Austria, 2Leopold-Franzens-
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OBJECTIVES: Despite the ﬂexibility of Discrete-Event-Simula-
tion it is rarely used in decision analytic modelling in health care.
To illustate the beneﬁts of applying this modelling approach,
treatment allocation strategies for patients with cardiovascular
disease are evaluated. This methodological study demonstrates
how capacity constraints effect cost-effectiveness and additional
parameters for decision-making. METHODS: Cost-effectiveness
analysis is usually done for separate patient subgroups assuming
unrestricted availability of capacities, or the capacity constrain-
sts are incorporated addressing only ﬁxed waiting times.
However, in “real-world” application, a successful new treat-
ment given to only one subgroup of patients can inﬂuence the
whole patient cohort over time. For example, when medical
advances reduce the need for repeated interventions and proce-
dures, it increases available capacity. Newly developed drug-
eluting stents (DES) show promising reductions in repeated
revascularizations in speciﬁc cohorts (i.e. diabetics). Treatment
allocation strategies or guidelines determine which patients will
receive DES versus the alternative bare-metal stents (BMS). A
Discrete-Event-Simulation is used to estimate the outcome of
treatment allocation strategies for cardiovascular disease includ-
ing the long-term costs and effects of the procedures, utilization
factors and budgetary information. The simulation assumes
several capacity restrictions and takes into account daily patient
arrivals and how they effect the system as a whole. RESULTS:
In the stent simulation, a hypothetical capacity limitation for car-
diovascular intervention changes the ranking of efﬁcient treat-
ment strategies in such a way that certain strategies become
dominated. Therefore, these treatment options should not be
taken into consideration. Furthermore, evaluating treatment
strategies has the advantage of generating not only cost-effec-
tiveness outcomes but also utilization and budgetary impact
within the same simulation. CONCLUSIONS: Discrete-Event-
Simulation provides a wide range of multiple perspective out-
comes. In comparison to Markov and Decision-tree models,
capacities can be explicitly incorporated. This can change the rel-
ative cost- effectiveness results and has signiﬁcant impact on
decision-making.
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TOWARDS A MODELLED ECONOMIC EVALUATION TO
IDENTIFY THE OPTIMAL POPULATION FOR SCREENING OF
CORONARY ARTERY DISEASE
Tilden D1, Pascoe K1, Higashi MK2, Marelli C3, Kennedy L3,
Scheijbeler H1, Aristides M1
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OBJECTIVES: Currently, only symptomatic patients are
screened for CAD, leaving those asymptomatic but at risk
patients unscreened and therefore unaware of their disease
burden. Improved asymptomatic screening is an area of unmet
medical need, given that 50% of CAD patients present with a
myocardial infarction as their ﬁrst symptom. Our objective was
to develop an epidemiological and economic model to describe
the cost-effectiveness of screening for coronary artery disease in
at-risk populations. METHODS: A Markov microsimulation
model was developed to compare CAD screening strategies for
asymptomatic patients. The screening algorithm is deﬁned based
on its ability to risk stratify the population as measured by the
area under the receiver operating characteristic curve. The struc-
ture of the economic model links three main hypotheses: 1)
screening for CAD provides improved risk stratiﬁcation; 2);
which leads to initiation of effective and cost-effective interven-
tions; and 3) effective interventions reduce the burden of CAD.
Outcomes are measured as incidence of major adverse cardio-
vascular events (MACE). The population in the model is deﬁned
according to age, sex, diabetes status and ethnicity. The eco-
nomic model can be calculated for a population with any com-
bination of these risk factors. RESULTS: On the basis of United
States CAD registry data, the model identiﬁed segments of the
population with the highest incidence of CAD and therefore with
the greatest capacity to beneﬁt from CAD screening. These seg-
ments are deﬁned according to observable risk factors meaning
they can be used to identify a population eligible for CAD screen-
ing. CONCLUSIONS: Screening for CAD has the potential to
reduce disease burden and save lives. The model may be a useful
tool to 1) improve risk stratiﬁcation techniques for asympto-
matic screening; 2) identify populations where screening may be
cost-effective; and 3) identify areas where clinical data is needed
to support model validation.
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OBJECTIVE: To identify and characterize subclasses of patients
with dyslipidemia in a nationally representative sample using
Latent Class Analysis (LCA). METHODS: Dyslipidemia patients
were identiﬁed from a national database of electronic medical
records containing diagnosis, lab and medication information in
primary care setting from 1997 to 2004. LCA was applied to
patient classiﬁcation based on patient demographics, biomarker
measures (low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), total cholesterol (TC),
and triglyceride (TG)), and pre-existing coronary heart disease
(CHD), diabetes and hypertension. RESULTS: There were
72,533 patients included in this analysis. All information indices
and Lo-Mendell-Rubin test consistently suggested that a 5-class
model ﬁt the data best. Patients were classiﬁed into one of the
ﬁve classes with sizes of 17.7%, 9.6%, 29.4%, 32.6% and
10.8%, respectively. Patients in Class 1 were featured with
34.4% of HDL-C and 39.5% of TG abnormalities and high
prevalence of CHD (29.6%), diabetes (31.5%), and hyperten-
sion (78.2%). Patients in Class 2 shared similar lipid-proﬁle as
those in Class 1, but smaller percent of them carried co-mor-
bidities. Classes 3 and 4 were dominated by those with high
LDL-C and TC, but higher percent of patients in Class-3 had co-
morbidities. Class 5 was characterized by patients with abnor-
malities for all four biomarkers (80.0% for LDL-C, 76.8% for
HDL-C; 99.4% for TC, and 81.4% for TG). Patients in Classes
1 and 3 were more likely on antidyslipidemics at diagnosis, sug-
gesting that co-morbid CHD, diabetes and hypertension are
strong predictors of pharmacotherapy in primary care setting.
CONCLUSIONS: LCA appears to offer a useful approach to
studying case-mix of patients with dyslipidemia by classifying
patients into clinically similar sub-groups, which might provide
better insights to understand unmet needs and identify ap-
propriate treatment options. Our ﬁndings suggest that co-
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morbidities play a major role in driving antidyslipidemic use in
primary care setting.
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DERIVING UTITLITY VALUES FOR USE IN A MARKOV MODEL
FOR EXPLORING THE CLINICAL CONSEQUENCES OF
RIMONABANT IN ADDITION TO DIET AND EXERCISE IN
OVERWEIGHT OR OBESE SUBJECTS
McEwan P1, Nicholls C2, Getsios D3, Caro JJ3
1Cardiff Research Consortium, Cardiff, UK, 2Sanoﬁ-Aventis, Guildford
Surrey, UK, 3Caro Research Institute, Concord, MA, USA
OBJECTIVES: SHAPE is designed to predict long-term clinical
outcomes of management with rimonabant of cardiovascular
risk in overweight or obese subjects. It is a lifetime Markov
model with monthly cycles incorporating at risk, diabetes, car-
diovascular disease and mortality states, and using Framingham
and UKPDS risk equations. The objective of this study was to
derive utility estimates for the model’s health states based on
patients similar to those in rimonabant’s trials. METHODS:
Mean health utility (EQ5D) values were obtained from 36,294
subjects in the Health Outcomes Data Repository Database
(HODaR) of whom 4991 had either an MI, stroke, TIA or
angina event with no previous inpatient history. The HODaR
project collects data from patients who have attended the Cardiff
and Vale NHS Trust in Wales. Utility values associated with spe-
ciﬁc BMI levels were also derived from multivariate analysis on
subjects with a BMI ≥27 kg/m2 adjusting for age, sex and dia-
betes status. RESULTS: Mean age-related health utility was
0.719 for an acute MI event, 0.709 for stroke, 0.698 for TIA,
0.709 for angina and 0.776 for diabetes (with no prior compli-
cations or inpatient history). Mean age adjusted utility decre-
ments associated with these end points were 0.072, 0.185, 0.088,
0.126 and 0.041 for acute MI, stroke, TIA, angina and diabetes
respectively. For BMI, a decrement of 0.014 utilities was esti-
mated and this decrement reﬂects a 1 unit increase in BMI. CON-
CLUSION: This study provides contemporary and relevant
utility values for cardiovascular modeling. The values were
derived from clinical endpoints matching those included in the
model and are well suited to models using Framingham or
UKPDS risk equations.
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OBJECTIVES: The Medication Compliance Questionnaire
(MCQ) measures concepts that may be related to medication
compliance by investigating subjects’ motivation, barriers, atti-
tudes, and beliefs regarding compliance. In the current study, the
MCQ was administered in The Netherlands primarily via postal
survey. However, due to low response rate to postal surveys in
Italy, the MCQ was planned to be administered there primarily
via telephone interviews. The primary goal of the study was to
evaluate the equivalence of the postal mode of the MCQ against
the telephone interview mode, to determine whether the results
could be compared cross culturally. METHODS: Sixty subjects
in Italy who responded to a postal administration of the MCQ
were randomly assigned to one of two groups. Thirty subjects
were administered the MCQ again approximately one week later
by post and the remaining 30 subjects were administered the
questionnaire again approximately one week later by telephone.
RESULTS: As expected, results showed that the telephone mode
of administration resulted in more complete data. Mail admin-
istration resulted in per item missing data rates of 3.3–23.3%
while the phone administration yielded 100% response rates on
all except one question, which was missing only one response.
A difference in the consistency of responses across modes was
found, with more consistency observed in the same mode
between ﬁrst and second administrations compared to alternate
modes. There was also evidence of a response shift in the tele-
phone administration mode including evidence for socially desir-
able response bias. CONCLUSIONS: Based on the results of this
study, it is recommended that the results from the telephone
administration not be considered equivalent to the mail admin-
istration without further examination. It is not advised to make
direct comparisons of MCQ responses between countries
without taking the potential impact of mode of administration
into account.
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VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL
AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATIN-
TREATED PATIENTS WITH PERSISTENTLY LOW HDL-C
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OBJECTIVE: To help health care decision-makers assess the
cost-effectiveness of HDL-c raising therapy, a model was devel-
oped to project lifetime clinical and economic beneﬁts of adding
an HDL-c raising drug in statin-treated patients with persistently
low HDL-c. METHODS: We developed a simulation model
made of two analytic decision sub-models. The ﬁrst sub-model
(Monte-Carlo) created a cohort of patients based on lipid levels
after drug treatment. The second sub-model (Markov) estimated
long-term clinical and cost outcomes (Framingham risk equa-
tions). Validation analyses were performed. RESULTS: Internal
validation: in patients with no history of CVD, the model pre-
dicted a 2 years risk of CHD events of 1.12% and 2.02% risk
for males and females respectively versus 1% and 2% in the
Framingham study. In patients with a history of CVD, the model
predicted 2-year risk of CHD events of 9.15% and 3.20% for
males and females respectively versus 10 and 3.5% respectively
in the published values. External validation: 1) in patients with
low HDL-c, the model predicted a 2.32% risk for CHD events
associated with each 1 mg/dL increment in HDL-c versus 2–3%
in a published meta-analysis 2) by recreating the 4S cohort char-
acteristics and simvastatin treatment effects, the model predicted
cumulative incidences of 14.2% for non-fatal and 5.5% for fatal
CHD events versus 15.9% and 5.0% in the 4S. CONCLU-
SIONS: Based on our validations, this computer simulation
model appears to be a valuable and accurate tool to help evalu-
ate HDL-c raising therapy for patients with persistently low
HDL-c despite statin treatment.
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OBJECTIVES: Lack of adherence is a major determinant of
inadequate control of cardiovascular risk factors. The aim of this
study is to evaluate the level of therapeutic compliance among
patients with mild to moderate hypertension (HT) and/or dis-
lipidemia (DL), in a primary care setting in daily medical prac-
tice, and to determine factors associated with TC. METHODS:
